Advertisement

Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia

      Purpose

      This multi-institutional observational study conducted among 11 countries in East and Southeast Asia aimed to assess the clinical outcomes of prophylactic extended-field concurrent chemoradiation therapy using weekly cisplatin for patients with locally advanced cervical cancer.

      Methods and Materials

      Between October 2007 and May 2016, 106 patients with untreated squamous cell carcinoma of the cervix were enrolled in the present study. Radiation therapy consisted of pelvic irradiation (total dose, 50 Gy in 25 fractions including central shielding), prophylactic paraortic regional irradiation (36-40 Gy in 20 fractions), and either high- or low-dose-rate intracavitary brachytherapy (ICBT) according to institutional practice. The planned point A dose was 21 to 28 Gy in 3 to 4 fractions for high-dose-rate ICBT and 40 to 41 Gy in 1 to 2 fractions for low-dose-rate ICBT. Five cycles of weekly cisplatin (40 mg/m2) were administered during the radiation therapy course.

      Results

      A total of 106 patients were enrolled. Of these, 9 had major protocol violations and 2 did not receive treatment because of worsened general condition. Thus, 95 patients were evaluable. The median follow-up was 56 months. Of the 95 patients, 76 (80%) received 4 or 5 cycles of chemotherapy. Acute grade 3 leukopenia was observed in 20 of the patients (21%), and late grade 3 gastrointestinal toxicity was observed in 3%. The 2-year local control, progression-free survival, and overall survival rate for all patients were 96%, 78%, and 90%, respectively.

      Conclusions

      The results indicated that prophylactic extended-field concurrent chemoradiation therapy using weekly cisplatin is feasible and effective for patients with locally advanced cervical cancer in East and Southeast Asia.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • International Agency for Research on Cancer
        GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 v1.0.
        (Available at:)
        http://globocan.iarc.fr/
        Date accessed: May 7, 2018
        • Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration
        Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data from 18 randomized trials.
        J Clin Oncol. 2008; 26: 5802-5812
        • Rose P.G.
        • Ali S.
        • Watkins E.
        • et al.
        Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: A gynecologic oncology group study.
        J Clin Oncol. 2007; 25: 2804-2810
        • Whitney C.W.
        • Sause W.
        • Bundy B.N.
        • et al.
        Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A gynecologic oncology group and southwest oncology group study.
        J Clin Oncol. 1999; 17: 1339-1348
        • Rose P.G.
        • Bundy B.N.
        • Watkins E.B.
        • et al.
        Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
        N Engl J Med. 1999; 340: 1144-1153
        • Morris M.
        • Eifel P.J.
        • Lu J.
        • et al.
        Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.
        N Engl J Med. 1999; 340: 1137-1143
        • Kato S.
        • Ohno T.
        • Thephamongkhol K.
        • et al.
        Long-term follow-up results of a multi-institutional phase 2 study of concurrent chemoradiation therapy for locally advanced cervical cancer in east and southeast Asia.
        Int J Radiat Oncol Biol Phys. 2013; 87: 100-105
        • Kato S.
        • Ohno T.
        • Thephamongkhol K.
        • et al.
        Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in east and southeast Asia.
        Int J Radiat Oncol Biol Phys. 2010; 77: 751-757
        • Ohno T.
        • Wakatsuki M.
        • Thinh D.H.
        • et al.
        Concurrent chemoradiotherapy for T3-4 and N0-1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia.
        J Radiat Res. 2016; 57: 44-49
        • Ohno T.
        • Thinh D.H.
        • Kato S.
        • et al.
        Radiotherapy concurrently with weekly cisplatin, followed by adjuvant chemotherapy, for N2-3 nasopharyngeal cancer: A multicenter trial of the Forum for Nuclear Cooperation in Asia.
        J Radiat Res. 2013; 54: 467-473
        • Ohno T.
        • Nakano T.
        • Kato S.
        • et al.
        Accelerated hyperfractionated radiotherapy for cervical cancer: Multi-institutional prospective study of Forum for Nuclear Cooperation in Asia among eight Asian countries.
        Int J Radiat Oncol Biol Phys. 2008; 70: 1522-1529
        • Nakano T.
        • Kato S.
        • Cao J.
        • et al.
        A regional cooperative clinical study of radiotherapy for cervical cancer in east and south-east Asian countries.
        Radiother Oncol. 2007; 84: 314-319
        • Vidaurreta J.
        • Bermudez A.
        • di Paola G.
        • Sardi J.
        Laparoscopic staging in locally advanced cervical carcinoma: A new possible philosophy?.
        Gynecol Oncol. 1999; 75: 366-371
        • Sakuragi N.
        • Satoh C.
        • Takeda N.
        • et al.
        Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy.
        Cancer. 1999; 85: 1547-1554
        • Berman M.L.
        • Keys H.
        • Creasman W.
        • DiSaia P.
        • Bundy B.
        • Blessing J.
        Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study).
        Gynecol Oncol. 1984; 19: 8-16
        • Wakatsuki M.
        • Kato S.
        • Ohno T.
        • et al.
        Difference in distant failure site between locally advanced squamous cell carcinoma and adenocarcinoma of the uterine cervix after C-ion RT.
        J Radiat Res. 2015; 56: 523-528
        • Small Jr., W.
        • Winter K.
        • Levenback C.
        • et al.
        Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: Results of arm 1 of RTOG 0116.
        Int J Radiat Oncol Biol Phys. 2007; 68: 1081-1087
        • Cox J.D.
        • Stetz J.
        • Pajak T.F.
        Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).
        Int J Radiat Oncol Biol Phys. 1995; 31: 1341-1346
        • Oh J.
        • Seol K.H.
        • Lee H.J.
        • Choi Y.S.
        • Park J.Y.
        • Bae J.Y.
        Prophylactic extended-field irradiation with concurrent chemotherapy for pelvic lymph node-positive cervical cancer.
        Radiat Oncol J. 2017; 35: 349-358
        • Poorvu P.D.
        • Sadow C.A.
        • Townamchai K.
        • Damato A.L.
        • Viswanathan A.N.
        Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes.
        Int J Radiat Oncol Biol Phys. 2013; 85: 1262-1268
        • Jensen L.G.
        • Hasselle M.D.
        • Rose B.S.
        • et al.
        Outcomes for patients with cervical cancer treated with extended-field intensity-modulated radiation therapy and concurrent cisplatin.
        Int J Gynecol Cancer. 2013; 23: 119-125
        • Beriwal S.
        • Gan G.N.
        • Heron D.E.
        • et al.
        Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer.
        Int J Radiat Oncol Biol Phys. 2007; 68: 166-171
        • Eifel P.J.
        • Winter K.
        • Morris M.
        • et al.
        Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of Radiation Therapy Oncology Group trial (RTOG) 90-01.
        J Clin Oncol. 2004; 22: 872-880
        • Grigsby P.W.
        • Heydon K.
        • Mutch D.G.
        • Kim R.Y.
        • Eifel P.
        Long-term follow-up of RTOG 92-10: Cervical cancer with positive para-aortic lymph nodes.
        Int J Radiat Oncol Biol Phys. 2001; 51: 982-987
        • Choi K.H.
        • Kim J.Y.
        • Lee D.S.
        • et al.
        Clinical impact of boost irradiation to pelvic lymph node in uterine cervical cancer treated with definitive chemoradiotherapy.
        Medicine (Baltimore). 2018; 97: e0517
        • Matsuo K.
        • Machida H.
        • Mandelbaum R.S.
        • Konishi I.
        • Mikami M.
        Validation of the 2018 FIGO cervical cancer staging system.
        Gynecol Oncol. 2019; 152: 87-93
        • Wakatsuki M.
        • Kato S.
        • Kiyohara H.
        • et al.
        Clinical trial of prophylactic extended-field carbon-ion radiotherapy for locally advanced uterine cervical cancer (protocol 0508).
        PloS One. 2015; 10: e0127587
        • Lee J.
        • Lin J.B.
        • Chang C.L.
        • et al.
        Impact of para-aortic recurrence risk-guided intensity-modulated radiotherapy in locally advanced cervical cancer with positive pelvic lymph nodes.
        Gynecol Oncol. 2018; 148: 291-298
        • Duenas-Gonzalez A.
        • Zarba J.J.
        • Patel F.
        • et al.
        Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.
        J Clin Oncol. 2011; 29: 1678-1685
        • Lorvidhaya V.
        • Chitapanarux I.
        • Sangruchi S.
        • et al.
        Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: A randomized trial.
        Int J Radiat Oncol Biol Phys. 2003; 55: 1226-1232
        • Tangjitgamol S.
        • Katanyoo K.
        • Laopaiboon M.
        • et al.
        Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer.
        Cochrane Database Syst Rev. 2014; : CD010401
        • Calaguas M.J.
        • Gubat J.A.
        South east Asia, differing socioeconomic factors, differing access to radiotherapy: The Philippines, a microcosm.
        Sem Radiat Oncol. 2017; 27: 176-183

      Comments

      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.